Ibrance is a cancer medicine used to treat breast cancer when the cancer is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body). Ibrance can only be used when the cancer cells have receptors (targets) for certain hormones on their surface (HR-positive) and do not produce abnormally large quantities of a receptor called HER2 (HER \[human epidermal growth factor\] negative). Ibrance is used in the following ways: - together with an aromatase inhibitor (a hormonal medicine for cancer); - together with fulvestrant (another hormonal medicine for cancer) in patients who have previously been treated with a hormonal medicine. In women who have not yet reached menopause, a medicine called a luteinising hormone-releasing hormone agonist should also be given. Ibrance contains the active substance palbociclib.
Therapeutic Indication
### Therapeutic indication Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
Therapeutic Area (MeSH)
N/AATC Code
L01EF01
ATC Item
palbociclib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Palbociclib | N/A | 哌柏西利 |
EMA Name
Ibrance
Medicine Name
Ibrance
Aliases
N/ANo risk management plan link.
